Vergent Bioscience is positioned at the forefront of surgical oncology innovation, founded in 2016 and focused on revolutionizing cancer surgery through advanced imaging technology. Their flagship product, VGT-309, is a proprietary molecularly-targeted imaging molecule that distinguishes cancerous tissue from normal tissue during surgery, a critical need in improving surgical outcomes and cure rates.
The molecule targets enzymes overexpressed in tumors, causing a fluorescent dye to highlight cancerous areas. This allows for enhanced visualization, aiding surgeons in effectively removing cancerous tissue across various cancers, including lung, breast, ovarian, colorectal, and brain.
Vergent Bioscience addresses substantial clinical needs while offering solutions in open, laparoscopic, and robotic surgeries. With a recent $21.50M Series B investment led by prominent investors like Colle Capital and Intuitive, the company is poised for significant growth in the biotechnology sector, maintaining pricing flexibility to thrive in the value-based healthcare market.
